A Dal­las biotech halts TIL ther­a­py tri­als — shares crater near­ly 30%

A Texas biotech at­tempt­ing to cre­ate new cell ther­a­pies has hit pause on en­roll­ment in clin­i­cal tri­als be­cause of man­u­fac­tur­ing is­sues, and the com­pa­ny’s shares …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER